Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
pING-hHER3FL in Patients With Resected Malignancies
NCT03832855Phase 1Active, not recruiting
- Sponsor
- Herbert Lyerly
- Start
- Jul 2020
- Primary completion
- Mar 2026
- Modality
- Plasmid DNA, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pING-hHER3FL in cancer and solid tumor, sponsored by Herbert Lyerly. Primary endpoint: Rate of T and B cell activity at 12 months. Started Jul 2020; status: active, not recruiting.
02
Drugs
pING-hHER3FL
03
Conditions
cancersolid tumor
Beyond the preview
Go deeper on NCT03832855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03832855.